Hyperprogression after immunotherapy in patients with malignant tumors of digestive system

BACKGROUND: Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Zhi, Peng, Zhi, Gong, Jifang, Zhang, Xiaotian, Li, Jian, Lu, Ming, Lu, Zhihao, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637510/
https://www.ncbi.nlm.nih.gov/pubmed/31315610
http://dx.doi.org/10.1186/s12885-019-5921-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637510/
https://www.ncbi.nlm.nih.gov/pubmed/31315610
http://dx.doi.org/10.1186/s12885-019-5921-9

Ejemplares similares